Anti-angiogenic therapeutic strategies in hereditary hemorrhagic telangiectasia

Frontiers in Genetics

Volumn 5, Issue FEB, 2015, Pages

  Ardelean, Daniela S ^a   Letarte, Michelle ^a,b,c  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Alk1; Angiogenesis; Anti angiogenic therapy; Anti VEGF; Endoglin; HHT; Inflammation; VEGF

Indexed keywords

ACTIVIN RECEPTOR LIKE KINASE 1; ALPHA INTERFERON; ANGIOPOIETIN 2; ENDOGLIN; INFLIXIMAB; LENALIDOMIDE; PROPRANOLOL; TACROLIMUS; THALIDOMIDE; THROMBOSPONDIN 1; TIMOLOL; VASCULOTROPIN; VASCULOTROPIN ANTIBODY;

ANEMIA; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ARTERIOVENOUS MALFORMATION; BLOOD VESSEL INJURY; CAPILLARY DENSITY; CENTRAL NERVOUS SYSTEM DISEASE; CONSTIPATION; DEEP VEIN THROMBOSIS; DEMYELINATING DISEASE; DOWN REGULATION; DROWSINESS; DRUG MECHANISM; EPISTAXIS; GASTROINTESTINAL HEMORRHAGE; GENE MUTATION; HUMAN; HYPERTENSION; IMMUNOMODULATION; INFECTION; KIDNEY DISEASE; LIVER DYSFUNCTION; LYMPHOMA; NONHUMAN; PERIPHERAL NEUROPATHY; PROTEIN EXPRESSION; PROTEINURIA; RENDU OSLER WEBER DISEASE; REVIEW; RHEUMATIC DISEASE; SIGNAL TRANSDUCTION; SOMNOLENCE; THYROID DISEASE; UPREGULATION; WOUND DEHISCENCE;

ANIMALIA;

EID: 84923632600     PISSN: None     EISSN: 16648021     Source Type: Journal    
DOI: 10.3389/fgene.2015.00035     Document Type: Review

References (65)

1. Albinana, V., Recio-Poveda, L., Zarrabeitia, R., Bernabeu, C., and Botella, L. M. (2012). Propranolol as antiangiogenic candidate for the therapy of hereditary haemorrhagic telangiectasia. Thromb. Haemost. 108, 41-53. doi: 10.1160/TH11-11-0809
2. Albinana, V., Sanz-Rodriguez, F., Recio-Poveda, L., Bernabeu, C., and Botella, L. M. (2011). Immunosuppressor FK506 increases endoglin and activin receptor-like kinase 1 expression and modulates transforming growth factor-beta1 signaling in endothelial cells. Mol. Pharmacol. 79, 833-843. doi: 10.1124/mol.110.067447
3. Ardelean, D. S., Jerkic, M., Yin, M., Peter, M., Ngan, B., Kerbel, R. S.,et al. (2014a). Endoglin and activin receptor-like kinase 1 heterozygous mice have a distinct pulmonary and hepatic angiogenic profile and response to anti-VEGF treatment. Angiogenesis 17, 129-146. doi: 10.1007/s10456-013-9383-4
4. Ardelean, D. S., Yin, M., Jerkic, M., Peter, M., Ngan, B., Kerbel, R. S.,et al. (2014b). Anti-VEGF therapy reduces intestinal inflammation in Endoglin heterozygous mice subjected to experimental colitis. Angiogenesis 17, 641-659. doi: 10.1007/s10456-014-9421-x
5. Atkinson, C., Stewart, S., Upton, P. D., Machado, R., Thomson, J. R., Trembath, R. C.,et al. (2002). Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor. Circulation 105, 1672-1678. doi: 10.1161/01.CIR.0000012754.72951.3D
6. Bierer, B. E., Schreiber, S. L., and Burakoff, S. J. (1991). The effect of the immunosuppressant FK-506 on alternate pathways of T cell activation. Eur. J. Immunol. 21, 439-445. doi: 10.1002/eji.1830210228
7. Blanco, P., Palucka, A. K., Gill, M., Pascual, V., and Banchereau, J. (2001). Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science 294, 1540-1543. doi: 10.1126/science.1064890
8. Bose, P., Holter, J. L., and Selby, G. B. (2009). Bevacizumab in hereditary hemorrhagic telangiectasia. N. Engl. J. Med. 360, 2143-2144. doi: 10.1056/NEJMc0901421
9. Bowcock, S. J., and Patrick, H. E. (2009). Lenalidomide to control gastrointestinal bleeding in hereditary haemorrhagic telangiectasia: potential implications for angiodysplasias? Br. J. Haematol. 146, 220-222. doi: 10.1111/j.1365-2141.2009.07730.x
10. Carmeliet, P. (2003). Angiogenesis in health and disease. Nat. Med. 9, 653-660. doi: 10.1038/nm0603-653
11. Chen, C. H., Hsu, H. H., Hu, R. H., Lee, P. H., and Ho, C. M. (2012). Long-term therapy with thalidomide in hereditary hemorrhagic telangiectasia: case report and literature review. J. Clin. Pharmacol. 52, 1436-1440. doi: 10.1177/0091270011417824
12. Chen, S. T., Karnezis, T., and Davidson, T. M. (2011). Safety of intranasal bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis. Laryngoscope 121, 644-646. doi: 10.1002/lary.21345
13. Choi, E. J., Chen, W., Jun, K., Arthur, H. M., Young, W. L., and Su, H. (2014). Novel brain arteriovenous malformation mouse models for type 1 hereditary hemorrhagic telangiectasia. PLoS ONE 9:e88511. doi: 10.1371/journal.pone.0088511
14. Collin, O., and Bergh, A. (1996). Leydig cells secrete factors which increase vascular permeability and endothelial cell proliferation. Int. J. Androl. 19, 221-228. doi: 10.1111/j.1365-2605.1996.tb00466.x
15. D'Amato, R. J., Loughnan, M. S., Flynn, E., and Folkman, J. (1994). Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. U.S.A. 91, 4082-4085. doi: 10.1073/pnas.91.9.4082
16. Dupuis-Girod, S., Ambrun, A., Decullier, E., Samson, G., Roux, A., Fargeton, A. E.,et al. (2014). ELLIPSE Study: a phase 1 study evaluating the tolerance of bevacizumab nasal spray in the treatment of epistaxis in hereditary hemorrhagic telangiectasia. MAbs 6, 794-799. doi: 10.4161/mabs.28025
17. Dupuis-Girod, S., Ginon, I., Saurin, J. C., Marion, D., Guillot, E., Decullier, E.,et al. (2012). Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output. JAMA 307, 948-955. doi: 10.1001/jama.2012.250
18. Folkman, J., and Klagsbrun, M. (1987). Angiogenic factors. Science 235, 442-447. doi: 10.1126/science.2432664
19. Franchini, M., Frattini, F., Crestani, S., and Bonfanti, C. (2013). Novel treatments for epistaxis in hereditary hemorrhagic telangiectasia: a systematic review of the clinical experience with thalidomide. J. Thromb. Thrombolysis 36, 355-357. doi: 10.1007/s11239-012-0840-5
20. Friesel, R., Komoriya, A., and Maciag, T. (1987). Inhibition of endothelial cell proliferation by gamma-interferon. J. Cell Biol. 104, 689-696. doi: 10.1083/jcb.104.3.689
21. Garrido-Martin, E. M., Nguyen, H. L., Cunningham, T. A., Choe, S. W., Jiang, Z., Arthur, H. M.,et al. (2014). Common and distinctive pathogenetic features of arteriovenous malformations in hereditary hemorrhagic telangiectasia 1 and hereditary hemorrhagic telangiectasia 2 animal models-brief report. Arterioscler. Thromb. Vasc. Biol. 34, 2232-2236. doi: 10.1161/ATVBAHA.114.303984
22. Govani, F. S., and Shovlin, C. L. (2009). Hereditary haemorrhagic telangiectasia: a clinical and scientific review. Eur. J. Hum. Genet. 17, 860-871. doi: 10.1038/ejhg.2009.35
23. Han, C., Choe, S. W., Kim, Y. H., Acharya, A. P., Keselowsky, B. G., Sorg, B. S.,et al. (2014). VEGF neutralization can prevent and normalize arteriovenous malformations in an animal model for hereditary hemorrhagic telangiectasia 2. Angiogenesis 17, 823-830. doi: 10.1007/s10456-014-9436-3
24. Inoue, T., Murano, M., Narabayashi, K., Okada, T., Nouda, S., Ishida, K.,et al. (2013). The efficacy of oral tacrolimus in patients with moderate/severe ulcerative colitis not receiving concomitant corticosteroid therapy. Intern. Med. 52, 15-20. doi: 10.2169/internalmedicine.52.8555
25. Jerkic, M., Kabir, M. G., Davies, A., Yu, L. X., Mcintyre, B. A., Husain, N. W.,et al. (2011). Pulmonary hypertension in adult Alk1 heterozygous mice due to oxidative stress. Cardiovasc. Res. 92, 375-384. doi: 10.1093/cvr/cvr232
26. Kino, T., Hatanaka, H., Miyata, S., Inamura, N., Nishiyama, M., Yajima, T.,et al. (1987). FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J. Antibiot. (Tokyo) 40, 1256-1265. doi: 10.7164/antibiotics.40.1256
27. Komorowski, J., Jerczynska, H., Siejka, A., Baranska, P., Lawnicka, H., Pawlowska, Z.,et al. (2006). Effect of thalidomide affecting VEGF secretion, cell migration, adhesion and capillary tube formation of human endothelial EA.hy 926 cells. Life Sci. 78, 2558-2563. doi: 10.1016/j.lfs.2005.10.016
28. Lebrin, F., Srun, S., Raymond, K., Martin, S., Van Den Brink, S., Freitas, C.,et al. (2010). Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia. Nat. Med. 16, 420-428. doi: 10.1038/nm.2131
29. Lopez-Novoa, J. M., and Bernabeu, C. (2010). The physiological role of endoglin in the cardiovascular system. Am. J. Physiol. Heart Circ. Physiol. 299, H959-H974. doi: 10.1152/ajpheart.01251.2009
30. Maisel, A. S., Murray, D., Lotz, M., Rearden, A., Irwin, M., and Michel, M. C. (1991). Propranolol treatment affects parameters of human immunity. Immunopharmacology 22, 157-164. doi: 10.1016/0162-3109(91)90040-6
31. Massoud, O. I., Youssef, W. I., and Mullen, K. D. (2004). Resolution of hereditary hemorrhagic telangiectasia and anemia with prolonged alpha-interferon therapy for chronic hepatitis C. J. Clin. Gastroenterol. 38, 377-379. doi: 10.1097/00004836-200404000-00015
32. Mitchell, A., Adams, L. A., Macquillan, G., Tibballs, J., Vanden Driesen, R., and Delriviere, L. (2008). Bevacizumab reverses need for liver transplantation in hereditary hemorrhagic telangiectasia. Liver Transpl. 14, 210-213. doi: 10.1002/lt.21417
33. Nagy, J. A., Chang, S. H., Shih, S. C., Dvorak, A. M., and Dvorak, H. F. (2010). Heterogeneity of the tumor vasculature. Semin. Thromb. Hemost. 36, 321-331. doi: 10.1055/s-0030-1253454
34. Neumann, A. U., Lam, N. P., Dahari, H., Gretch, D. R., Wiley, T. E., Layden, T. J.,et al. (1998). Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 282, 103-107. doi: 10.1126/science.282.5386.103
35. Oh, S. P., Seki, T., Goss, K. A., Imamura, T., Yi, Y., Donahoe, P. K.,et al. (2000). Activin receptor-like kinase 1 modulates transforming growth factor-beta 1 signaling in the regulation of angiogenesis. Proc. Natl. Acad. Sci. U.S.A. 97, 2626-2631. doi: 10.1073/pnas.97.6.2626
36. Olitsky, S. E. (2012). Topical timolol for the treatment of epistaxis in hereditary hemorrhagic telangiectasia. Am.J.Otolaryngol. 33, 375-376. doi: 10.1016/j.amjoto.2011.10.011
37. Oosting, S., Nagengast, W., and De Vries, E. (2009). More on bevacizumab in hereditary hemorrhagic telangiectasia. N. Engl. J. Med. 361, 931-932. doi: 10.1056/NEJMc091271
38. Papa, A., Felice, C., Marzo, M., and Guidi, L. (2010). A case of hereditary hemorrhagic telangiectasia associated with Crohn's disease successfully treated with infliximab. Am. J. Gastroenterol. 105:1904. doi: 10.1038/ajg.2010.155
39. Park, S. O., Wankhede, M., Lee, Y. J., Choi, E. J., Fliess, N., Choe, S. W.,et al. (2009). Real-time imaging of de novo arteriovenous malformation in a mouse model of hereditary hemorrhagic telangiectasia. J. Clin. Invest. 119, 3487-3496. doi: 10.1172/JCI39482
40. Pavlidis, E. T., and Pavlidis, T. E. (2013). Role of bevacizumab in colorectal cancer growth and its adverse effects: a review. World J. Gastroenterol. 19, 5051-5060. doi: 10.3748/wjg.v19.i31.5051
41. Platanias, L. C. (2005). Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat. Rev. Immunol. 5, 375-386. doi: 10.1038/nri1604
42. Posadas Salas, M. A., and Srinivas, T. R. (2014). Update on the clinical utility of once-daily tacrolimus in the management of transplantation. Drug Des. Devel. Ther. 8, 1183-1194. doi: 10.2147/DDDT.S55458
43. Reisinger, K., Baal, N., Mckinnon, T., Munstedt, K., and Zygmunt, M. (2007). The gonadotropins: tissue-specific angiogenic factors? Mol. Cell Endocrinol. 269, 65-80. doi: 10.1016/j.mce.2006.11.015
44. Retornaz, F., Rinaldi, Y., and Duvoux, C. (2009). More on bevacizumab in hereditary hemorrhagic telangiectasia. N. Engl. J. Med. 361, 931; author reply 931-932. doi: 10.1056/NEJMc091271
45. Rutella, S., Fiorino, G., Vetrano, S., Correale, C., Spinelli, A., Pagano, N.,et al. (2011). Infliximab therapy inhibits inflammation-induced angiogenesis in the mucosa of patients with Crohn's disease. Am. J. Gastroenterol. 106, 762-770. doi: 10.1038/ajg.2011.48
46. Sadick, H., Naim, R., Gossler, U., Hormann, K., and Riedel, F. (2005a). Angiogenesis in hereditary hemorrhagic telangiectasia: VEGF165 plasma concentration in correlation to the VEGF expression and microvessel density. Int. J. Mol. Med. 15, 15-19.
47. Sadick, H., Riedel, F., Naim, R., Goessler, U., Hormann, K., Hafner, M.,et al. (2005b). Patients with hereditary hemorrhagic telangiectasia have increased plasma levels of vascular endothelial growth factor and transforming growth factor-beta1 as well as high ALK1 tissue expression. Haematologica 90, 818-828.
48. Scallon, B., Cai, A., Solowski, N., Rosenberg, A., Song, X. Y., Shealy, D.,et al. (2002). Binding and functional comparisons of two types of tumor necrosis factor antagonists. J. Pharmacol. Exp. Ther. 301, 418-426. doi: 10.1124/jpet.301.2.418
49. Schonthaler, H. B., Huggenberger, R., Wculek, S. K., Detmar, M., and Wagner, E. F. (2009). Systemic anti-VEGF treatment strongly reduces skin inflammation in a mouse model of psoriasis. Proc. Natl. Acad. Sci. U.S.A. 106, 21264-21269. doi: 10.1073/pnas.0907550106
50. Shao, E. S., Lin, L., Yao, Y., and Bostrom, K. I. (2009). Expression of vascular endothelial growth factor is coordinately regulated by the activin-like kinase receptors 1 and 5 in endothelial cells. Blood 114, 2197-2206. doi: 10.1182/blood-2009-01-199166
51. Siamakpour-Reihani, S., Caster, J., Bandhu Nepal, D., Courtwright, A., Hilliard, E., Usary, J.,et al. (2011). The role of calcineurin/NFAT in SFRP2 induced angiogenesis-a rationale for breast cancer treatment with the calcineurin inhibitor tacrolimus. PLoS ONE 6:e20412. doi: 10.1371/journal.pone.0020412
52. Simonds, J., Miller, F., Mandel, J., and Davidson, T. M. (2009). The effect of bevacizumab (Avastin) treatment on epistaxis in hereditary hemorrhagic telangiectasia. Laryngoscope 119, 988-992. doi: 10.1002/lary.20159
53. Skaro, A. I., Marotta, P. J., and Mcalister, V. C. (2006). Regression of cutaneous and gastrointestinal telangiectasia with sirolimus and aspirin in a patient with hereditary hemorrhagic telangiectasia. Ann. Intern. Med. 144, 226-227. doi: 10.7326/0003-4819-144-3-200602070-00030
54. Sorensen, L. K., Brooke, B. S., Li, D. Y., and Urness, L. D. (2003). Loss of distinct arterial and venous boundaries in mice lacking endoglin, a vascular-specific TGFbeta coreceptor. Dev. Biol. 261, 235-250. doi: 10.1016/S0012-1606(03)00158-1
55. Storch, C. H., and Hoeger, P. H. (2010). Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action. Br. J. Dermatol. 163, 269-274. doi: 10.1111/j.1365-2133.2010.09848.x
56. Suppressa, P., Liso, A., and Sabba, C. (2011). Low dose intravenous bevacizumab for the treatment of anaemia in hereditary haemorrhagic telangiectasia. Br. J. Haematol. 152, 365. doi: 10.1111/j.1365-2141.2010.08481.x
57. Tanaka, H., Tsuruga, K., Aizawa-Yashiro, T., Watanabe, S., and Imaizumi, T. (2012). Treatment of young patients with lupus nephritis using calcineurin inhibitors. World J. Nephrol. 1, 177-183. doi: 10.5527/wjn.v1.i6.177
58. Teo, S. K. (2005). Properties of thalidomide and its analogues: implications for anticancer therapy. AAPS J. 7, E14-E19. doi: 10.1208/aapsj070103
59. Toporsian, M., Jerkic, M., Zhou, Y. Q., Kabir, M. G., Yu, L. X., Mcintyre, B. A.,et al. (2010). Spontaneous adult-onset pulmonary arterial hypertension attributable to increased endothelial oxidative stress in a murine model of hereditary hemorrhagic telangiectasia. Arterioscler. Thromb. Vasc. Biol. 30, 509-517. doi: 10.1161/ATVBAHA.109.200121
60. Tual-Chalot, S., Mahmoud, M., Allinson, K. R., Redgrave, R. E., Zhai, Z., Oh, S. P.,et al. (2014). Endothelial depletion of Acvrl1 in mice leads to arteriovenous malformations associated with reduced endoglin expression. PLoS ONE 9:e98646. doi: 10.1371/journal.pone.0098646
61. Wheatley-Price, P., Shovlin, C., and Chao, D. (2005). Interferon for metastatic renal cell cancer causing regression of hereditary hemorrhagic telangiectasia. J. Clin. Gastroenterol. 39, 344-345. doi: 10.1097/01.mcg.0000155137.73433.36
62. Willrich, M. A., Murray, D. L., and Snyder, M. R. (2014). Tumor necrosis factor inhibitors: clinical utility in autoimmune diseases. Transl. Res. 165, 270-282. doi: 10.1016/j.trsl.2014.09.006
63. Xie, W., Xie, H., Liu, F., Li, W., Dan, J., Mei, Y.,et al. (2013). Propranolol induces apoptosis of human umbilical vein endothelial cells through downregulation of CD147. Br. J. Dermatol. 168, 739-748. doi: 10.1111/bjd.12193
64. Yabu, T., Tomimoto, H., Taguchi, Y., Yamaoka, S., Igarashi, Y., and Okazaki, T. (2005). Thalidomide-induced antiangiogenic action is mediated by ceramide through depletion of VEGF receptors, and is antagonized by sphingosine-1-phosphate. Blood 106, 125-134. doi: 10.1182/blood-2004-09-3679
65. Yano, K., Brown, L. F., Lawler, J., Miyakawa, T., and Detmar, M. (2003). Thrombospondin-1 plays a critical role in the induction of hair follicle involution and vascular regression during the catagen phase. J. Invest. Dermatol. 120, 14-19. doi: 10.1046/j.1523-1747.2003.12045.x